Cedars-Sinai Medical Center
cedars-sinai.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
449
Active
121
Phase 3
14
Total enrollment
83,896
Pipeline matrix
Showing 40 of 53 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| High dose potent statin | — | — | — | — | — | 1 | |
| ACE-I | — | — | — | — | — | 1 | |
| Aspirin 81 enteric coated tablet daily | — | — | — | — | — | 1 | |
| Bupivacaine liposome injectable suspension | — | — | — | — | — | 1 | |
| Instillation of Bupivacaine with epinephrine over the diaphragm | — | — | — | — | — | 1 | |
| CYTALUX™ | — | — | — | — | — | 1 | |
| Bupivacaine | — | — | — | — | 3 | ||
| Dasatinib 100 MG | — | — | — | — | — | 1 | |
| Quercetin 1000mg | — | — | — | — | — | 1 | |
| Mirabegron | — | — | — | — | — | 2 | |
| Thymoglobulin | — | — | — | — | 2 | ||
| Carboplatin | — | — | — | — | 3 | ||
| Fisetin | — | — | — | — | — | 1 | |
| Seliciclib | — | — | — | — | — | 1 | |
| Mycophenolate Mofetil | — | — | — | — | — | 1 | |
| Tacrolimus | — | — | — | — | — | 1 | |
| Sirolimus | — | — | — | — | — | 1 | |
| Corticosteroids | — | — | — | — | — | 1 | |
| Zinc | — | — | — | — | — | 1 | |
| Nicotinamide riboside | — | — | — | — | — | 1 | |
| Mesna | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | — | 1 | |
| Filgrastim | — | — | — | — | — | 1 | |
| Fludarabine | — | — | — | — | — | 1 | |
| Methylprednisolone | — | — | — | — | — | 1 | |
| Diphenhydramine | — | — | — | — | — | 1 | |
| Acetaminophen | — | — | — | — | — | 1 | |
| anti-thymocyte globulin | — | — | — | — | — | 1 | |
| lymphocyte immune globulin | — | — | — | — | — | 1 | |
| Peripheral Blood Stem Cell | — | — | — | — | — | 1 | |
| Cytoxan | — | — | — | — | — | 1 | |
| Ivonescimab | — | — | — | — | — | 1 | |
| Docetaxel | — | — | — | — | — | 1 | |
| Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray | — | — | — | — | — | 1 | |
| Vytorin | — | — | — | — | — | 1 | |
| Ezetimibe | — | — | — | — | — | 1 | |
| Carvedilol | — | — | — | — | — | 1 | |
| Terazosin therapy | — | — | — | — | — | 1 | |
| S-adenosyl-L-methionine | — | — | — | — | — | 1 | |
| Cisplatin Chemotherapy | — | — | — | — | — | 1 |
13 more active programs hidden
Next readouts
- 2025-12-10
- 2025-12-31
- 2026-03-10
- 2026-03-31
- 2026-06-01
- 2026-06-30
- 2026-06-30
- 2026-07
- 2026-07
- 2026-07-15
Top conditions
- Breast Cancer13
- Coronary Artery Disease12
- Hypertension10
- Cancer10
- Depression10
- Prostate Cancer10
- Acromegaly9
- Pain7
Frequently asked questions about Cedars-Sinai Medical Center
- How many clinical trials does Cedars-Sinai Medical Center have on ClinicalTrials.gov?
- Cedars-Sinai Medical Center is listed as the lead sponsor on 449 clinical trials in ClinicalTrials.gov, 121 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Cedars-Sinai Medical Center's trials are in Phase 3?
- 14 of Cedars-Sinai Medical Center's trials are in Phase 3, spread across 53 active drug programs.
- What therapeutic areas does Cedars-Sinai Medical Center focus on?
- Cedars-Sinai Medical Center's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Coronary Artery Disease, Hypertension, Cancer, Depression.
- When are Cedars-Sinai Medical Center's next clinical trial readouts?
- Cedars-Sinai Medical Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Terazosin Effect on Cardiac Changes in Early Parkinson's Disease”, expected around 2025-12-10.